文献速递神经免疫

精神疾病中神经元抗体的检测:不确定的发现与启示

Searching for Neuronal Antibodies in Psychiatric Diseases: Uncertain Findings and Implications.
PubMed 文献 · Neurology · 2023-06-23

本文讨论在精神疾病中检测神经元表面抗体的不确定性,指出这些检测在精神疾病中未定义任何疾病或影响诊疗,并列举五类抗体检测问题:健康人血清中GAD65、TPO抗体阳性率8%-13%,VGKC抗体须检测LGI1或CASPR2才有用,Ma2、Zic4、SOX1商业检测假阳性多,GlyR抗体仅查血清时疾病特异性不明,未知抗原抗体缺乏疾病特异性和对照。强调临床判断重于抗体结果。

要点

  • 健康人血清中GAD65、TPO抗体阳性率8%-13%。
  • VGKC抗体须检测LGI1或CASPR2才有用。
  • Ma2、Zic4、SOX1商业检测假阳性多,GlyR抗体仅查血清时特异性不明。

核心结论

  • 在精神疾病中,抗体的表面检测未定义任何疾病,也未影响患者的诊断和治疗,应强调临床判断重于抗体发现。

研究设计与样本

  • 本文为综述,讨论精神疾病中神经元抗体检测的问题与局限性。

主要发现

  • 一些抗体(GAD65、TPO)在8%-13%健康人血清中出现。
  • VGKC抗体除非检测LGI1或CASPR2,否则无用。
  • Ma2、Zic4和SOX1抗体的商业临床检测导致大量假阳性结果。
  • GlyR抗体仅检测血清时疾病特异性不明确。
  • 针对内皮、星形胶质细胞、髓鞘纤维或海马和小脑颗粒细胞未知抗原的抗体的意义因缺乏疾病特异性和适当对照而受到质疑。

关键数值与推荐

  • 自身免疫性脑炎中抗神经元表面蛋白抗体与特定疾病相关,通常对治疗有反应,并与抗原相关的合并症相关。
  • 精神疾病中抗体的表面检测未定义任何疾病或影响诊断治疗。

临床怎么用

  • 上述局限性和问题常是神经科会诊的原因,应强调临床判断重于抗体发现。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, neurology and psychiatry journals have been inundated with reports on individual symptoms of autoimmune encephalitis (AE) that are described as distinct entities such as autoimmune psychosis, obsessive-compulsive disorders, or depression. It is unquestionable that for AE the demonstration of antibodies against neuronal-surface proteins is intrinsically linked to distinct disorders (some defining new diseases) that are usually treatment-responsive and associate with comorbidities that vary according to the antigen. By contrast, for psychiatric diseases, the apparent detection of antibodies has not defined any disorder or affected the diagnosis and treatment of patients. Although these studies frequently use anti-N-methyl-D-aspartate receptor encephalitis to rationalize the findings, they rarely adopt the same rigorous investigations or address the clinical and pathogenic significance of the antibodies or discuss the limitations related to the biological sample or antibody-testing techniques. It is imperative to consider (1) some antibodies (GAD65, TPO) occur in serum of 8%-13% of healthy people; (2) VGKC antibodies are not useful unless LGI1 or CASPR2 are investigated; (3) commercial-clinical testing for Ma2, Zic4, and SOX1 antibodies causes a high number of false-positive results; (4) GlyR antibodies have unclear disease specificity when examined only in serum; and (5) the significance of antibodies against unknown antigens of endothelium, astrocytes, myelin fibers, or granule cells of hippocampus and cerebellum is questioned by the lack of disease specificity and appropriate controls. These limitations and problems are a frequent cause of neurologic consultations. Here we discuss some of these problems, emphasizing the importance of clinical judgment over antibody findings.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Guasp M, Dalmau J. Searching for Neuronal Antibodies in Psychiatric Diseases: Uncertain Findings and Implications. Neurology. 2023. PMID: 37353340. doi:10.1212/WNL.0000000000207486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。